Selected publications
Yıldız A, Hasani A, Hempel T, Köhl N, Beicht A, Becker R, Hubich-Rau S, Suchan M, Poleganov M, Sahin U, Beissert T
Molecular Therapy: Nucleic Acids 2024
Beck J, Diken M, Suchan M, Streuber M, Diken E, Kolb L, Allnoch L, Vascotto F, Peters D, Beißert T, Akilli-Öztürk Ö, Türeci Ö, Kreiter- S, Vormehr M, Sahin U
Cancer Cell, 2024
2023
Lang F, Sorn P, Schrörs B, Weber D, Kramer S, Sahin U, Löwer L
iScience, Volume 26, Issue 11, 2023
Muñoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, et al.
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
New England Journal of Medicine, 2023Picard FSR, Lutz V, Brichkina A, Neuhaus F, Ruckenbrod T, Hupfer A, Raifer H, Klein M, Bopp T, Pfefferle PI, Savai R, Prinz I, Waisman A, Moos S, Chang HD, Heinrich S, Bartsch DK, Buchholz M, Singh S, Tu M, Klein L, Bauer C, Liefke R, Burchert A, Chung HR, Mayer P, Gress TM, Lauth M, Gaida M, Huber M. IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Gut. 2023 Feb 9:gutjnl-2022-327855.
Saerchen V, Reindl L, Wiedemann S, Shanmugalingam S, Bukur T, Becker J, Suchan M, Ullrich E, Vogler M. Characterization of BV6-Induced Sensitization to the NK Cell Killing of Pediatric Rhabdomyosarcoma Spheroids. Cells 2023, 12(6), 906
2022
Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nature Reviews Drug Discovery, 2022
Muik A., Lui B., Wallisch A., Bacher M., Mühl J., Reinholz J., Ozhelvaci O., Beckmann N., Güimil Garcia R., Poran A., Shpyro S., Finlayson A., Cai H., Yang Q., Swanson K., Türeci Ö., Şahin U. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 2022; 375(6581):678-680
Weber D., Ibn-Salem J., Sorn P., Suchan M., Holtsträter C., Lahrmann U., Vogler I., Schmoldt K., Lang F., Schrörs B., Löwer M., Şahin U. Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens. Nat Biotechnol 2022;40(8):1276-1284
2021
Krienke C., Kolb L., Diken E., Streuber M., Kirchhoff S., Bukur T., Akilli-Öztürk Ö., Kranz L., Berger H., Petschenka J., Diken M., Kreiter S., Yogev N., Waisman A., Karikó K., Türeci Ö., Şahin U. A. Noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 2021; 371(6525):145-153.
Muik A., Wallisch A., Sänger B., Swanson K., Mühl J., Chen W., Cai H., Maurus D., Sarkar R., Türeci Ö., Dormitzer P., Şahin U. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 2021; 371(6534):1152-1153
Şahin U., Muik A., Vogler I., Derhovanessian E., Kranz L., Vormehr M., Quandt J., Bidmon N., et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 2021; 595(7868):572-577
Vogel A., Kanevsky I., Che Y., Swanson K., Muik A., Vormehr M., Kranz L., Walzer K., et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 2021; 592(7853):283-289
2020
Mulligan M., Lyke K., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Raabe V., et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020; 586(7830):589-593
Mulligan M., Lyke K., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Raabe V., Bailey R., Swanson K., Li P., Koury K., Kalina W., Cooper D., Fontes-Garfias C., Shi P., Türeci Ö., Tompkins K., Walsh E., Frenck R., Falsey A., Dormitzer P., Gruber W., Şahin U., Jansen K. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020; 586(7830):589-593
Reinhard K., Rengstl B., Oehm P., Michel K., Billmeier A., Hayduk N., Klein O., Kuna K., Ouchan Y., Wöll S., Christ E., Weber D., Suchan M., Bukur T., Birtel M., Jahndel V., Mroz K., Hobohm K., Kranz L., Diken M., Kühlcke K., Türeci Ö., Şahin U. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 2020;367(6476):446-453
Şahin U., Muik A., Derhovanessian E., Vogler I., Kranz L., Vormehr M., Baum A., Pascal K., et al. COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses. Nature 2020; 586(7830):594-599
Şahin U., Oehm P., Derhovanessian E., Jabulowsky R., Vormehr M., Gold M., Maurus D., Schwarck-Kokarakis D.,et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 2020; 585(7823):107-112
Şahin U., Oehm P., Derhovanessian E., Jabulowsky R., Vormehr M., Gold M., Maurus D., Schwarck-Kokarakis D., et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 2020; 585(7823):107-112